drugset
drugset / Trial / NCT05737706

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706 ↗

Phase 1 Terminated 63 enrolled Mirati Therapeutics Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.

Timeline

Start
2023-03-06
Primary completion
2025-03-10
Completion
2025-03-10

Outcome

Outcome not reported

Stopped: “Formulation challenges”

Drugs

EvaluationDrugModalityDoseRoute
Subject MRTX1133 Unknown — —

Indications

colorectal cancer non-small cell lung carcinoma pancreatic adenocarcinoma